Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally.
Flawless balance sheet with solid track record.
Share Price & News
How has Genomic Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: G7H has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: G7H underperformed the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: G7H underperformed the German Market which returned 17.1% over the past year.
Price Volatility Vs. Market
How volatile is Genomic Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Genomic Health undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: G7H (€57.3) is trading above our estimate of fair value (€27.27)
Significantly Below Fair Value: G7H is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: G7H is poor value based on its PE Ratio (41.3x) compared to the Biotechs industry average (35.3x).
PE vs Market: G7H is poor value based on its PE Ratio (41.3x) compared to the German market (20.6x).
Price to Earnings Growth Ratio
PEG Ratio: G7H is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: G7H is overvalued based on its PB Ratio (6.8x) compared to the DE Biotechs industry average (3.4x).
How is Genomic Health forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: G7H's forecast earnings growth (19.1% per year) is above the savings rate (0.2%).
Earnings vs Market: G7H's earnings (19.1% per year) are forecast to grow faster than the German market (13.2% per year).
High Growth Earnings: G7H's earnings are forecast to grow, but not significantly.
Revenue vs Market: G7H's revenue (8.5% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: G7H's revenue (8.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if G7H's Return on Equity is forecast to be high in 3 years time
How has Genomic Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: G7H has high quality earnings.
Growing Profit Margin: G7H's current net profit margins (12.8%) are higher than last year (4.9%).
Past Earnings Growth Analysis
Earnings Trend: G7H has become profitable over the past 5 years, growing earnings by 70.1% per year.
Accelerating Growth: G7H's earnings growth over the past year (203.5%) exceeds its 5-year average (70.1% per year).
Earnings vs Industry: G7H earnings growth over the past year (203.5%) exceeded the Biotechs industry 5.4%.
Return on Equity
High ROE: G7H's Return on Equity (16.2%) is considered low.
How is Genomic Health's financial position?
Financial Position Analysis
Short Term Liabilities: G7H's short term assets ($345.0M) exceed its short term liabilities ($57.9M).
Long Term Liabilities: G7H's short term assets ($345.0M) exceed its long term liabilities ($53.1M).
Debt to Equity History and Analysis
Debt Level: G7H is debt free.
Reducing Debt: G7H has not had any debt for past 5 years.
Inventory Level: G7H has a high level of physical assets or inventory.
Debt Coverage by Assets: G7H's debt is not covered by short term assets (assets are -4.8559500032169E+16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: G7H is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: G7H is profitable, therefore cash runway is not a concern.
What is Genomic Health's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate G7H's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate G7H's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if G7H's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if G7H's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of G7H's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kim Popovits (60yo)
Ms. Kimberly J. Popovits, also known as Kim, has served as the Chief Executive Officer and President at Genomic Health, Inc. since January 2009 and February 2002 respectively. Ms. Popovits serves as Direct ...
CEO Compensation Analysis
Compensation vs Market: Kim's total compensation ($USD4.76M) is above average for companies of similar size in the German market ($USD1.50M).
Compensation vs Earnings: Kim's compensation has been consistent with company performance over the past year.
|Co-Founder & Chief Scientific Officer||19.8yrs||US$1.65m||0.13% $2.9m|
|Chief Financial Officer||5.4yrs||US$1.93m||0.072% $1.6m|
|Chief Operating Officer||1.7yrs||US$2.21m||0.049% $1.1m|
|Chief U.S. Commercial Officer||8.3yrs||US$1.56m||0.014% $295.6k|
|VP & Chief Information Officer||1.8yrs||no data||no data|
|Vice President of Corporate Communications & Investor Relations||0yrs||no data||no data|
|Chief Legal Officer & Secretary||4.5yrs||no data||0.022% $481.9k|
|Chief Communications Officer||4.9yrs||no data||0.012% $250.6k|
|Vice President of Corporate Development||3yrs||no data||no data|
Experienced Management: G7H's management team is considered experienced (4.9 years average tenure).
|Independent Director||10.9yrs||US$272.95k||0.14% $3.0m|
|Independent Director||6.2yrs||US$285.95k||0.018% $385.4k|
|Independent Director||17.6yrs||US$280.95k||0.20% $4.3m|
|Lead Independent Director||18.8yrs||US$268.95k||0.11% $2.4m|
|Independent Director||7.3yrs||US$283.95k||0.024% $510.3k|
|Independent Director||3.4yrs||US$283.95k||no data|
|Independent Director||0.6yrs||no data||0.00056% $12.1k|
Experienced Board: G7H's board of directors are considered experienced (7.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.
Genomic Health, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Genomic Health, Inc.
- Ticker: G7H
- Exchange: DB
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.385b
- Listing Market Cap: US$2.164b
- Shares outstanding: 37.59m
- Website: https://www.genomichealth.com
Number of Employees
- Genomic Health, Inc.
- 301 Penobscot Drive
- Redwood City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GHDX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Sep 2005|
|G7H||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2005|
Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/11/09 20:43|
|End of Day Share Price||2019/11/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.